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Resistance to antiretroviral drugs remains an important limitation to successful human immunodeficiency
virus type 1 (HIV-1) therapy. Resistance testing can improve treatment outcomes for infected individuals. The
availability of new drugs from various classes, standardization of resistance assays, and the development of
viral tropism tests necessitate new guidelines for resistance testing. The International AIDS Society–USA
convened a panel of physicians and scientists with expertise in drug-resistant HIV-1, drug management, and
patient care to review recently published data and presentations at scientific conferences and to provide updated
recommendations. Whenever possible, resistance testing is recommended at the time of HIV infection diagnosis
as part of the initial comprehensive patient assessment, as well as in all cases of virologic failure. Tropism
testing is recommended whenever the use of chemokine receptor 5 antagonists is contemplated. As the roll
out of antiretroviral therapy continues in developing countries, drug resistance monitoring for both subtype
B and non–subtype B strains of HIV will become increasingly important.
A panel of the International AIDS Society–USA pub-
lished recommendations for HIV-1 drug resistance test-
ing in HIV-1–infected adults in 1998, 2000, and 2003
[1–3]. Since the 2003 publication, drug resistance test-
ing has become widespread in the developed world and
has been accepted as an important adjunct to the man-
agement of patients with detectable plasma viremia who
are receiving antiretroviral therapy. Moreover, person-
to-person transmission of drug-resistant viruses occurs
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in a variety of settings, including between adults and
from mother to child [4, 5], indicating that testing for
drug resistance before initiating therapy may be useful
even for treatment-naive patients. Novel resistance mu-
tations that confer resistance to older drugs continue
to be identified (figure 1), and newer-generation pro-
tease inhibitors (PIs) and reverse transcriptase inhibi-
tors have been developed to counteract mutations that
confer resistance to the older agents. Approval of agents
from new classes, like integrase strand transfer inhib-
itors (INSTIs) and entry inhibitors, assure that drug
resistance testing will become increasingly complex and
important in case management in the years ahead. Test-
ing methodologies have improved and are becoming
more sensitive, and tests for viral coreceptor use (i.e.,
tropism) have been introduced.
With increasing patient access to antiretroviral drugs
in the developing world, many of the same problems
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Table 1. Strength of recommendation and quality of evidence rating scale.
Category, grade Definition
Strength of recommendation
A Strong evidence to support the recommendation
B Moderate evidence to support the recommendation
C Insufficient evidence to support a recommendation
Quality of evidence
Ia,b Evidence from 1 randomized, controlled clinical trial
IIa,b Evidence from nonrandomized clinical trials; cohort or case-control studies
III Recommendation based on the panel’s analysis of accumulated evidence (expert opinion)
a Peer-reviewed publications.
b Presented in abstract form at peer-reviewed scientific meetings.
involving drug-resistant virus that are common in the devel-
oped world have begun to occur in the developing world, as
well. In addition, resistance patterns among the non–subtype
B strains of HIV-1, which are circulating more widely in de-
veloping countries, may differ from those seen among subtype
B strains in North America and Europe. Although resistance
testing is not yet widely employed in developing countries be-
cause of the costs involved, drug resistance will predictably
emerge as antiretroviral therapy is more widely introduced, and
the need for appropriate testing will increase. Expert advice is
important in the management of patients with drug-resistant
infection [8], but because it is not always available, this report
will attempt to provide updated recommendations for HIV-1
drug resistance testing and tropism testing in developed coun-
tries, with the anticipation that, over time, such recommen-
dations will also prove useful in developing countries.
METHODS
The panel was first convened by the International AIDS So-
ciety–USA (which is not related to the worldwide International
AIDS Society) in 1997 to develop evidence-based recommen-
dations for the assessment of HIV-1 drug susceptibility and the
management of drug-resistant HIV-1 infection in clinical prac-
tices in the developed world [1–3]. Panel members are not
compensated, and there is a process for panel member rotation.
Updated reports are initiated when enough new published or
presented information in the field accumulates to warrant re-
vising previous recommendations.
The panel was convened by conference call in mid-2007 and
met regularly thereafter to discuss new data published or pre-
sented at scientific conferences since its previous report [3].
Topic areas included new information about the prevalence of
drug resistance worldwide; new data on mechanisms of resis-
tance by drug class, including INSTI and entry inhibitor classes
that have become available since the previous report; devel-
opments in assays to determine viral tropism and replication
capacity; issues related to non–subtype B HIV-1; and updated
recommendations for the clinical use of HIV-1 drug resistance
and tropism testing. Individual panel members were appointed
to review topics to be considered. In some cases, pharmaceutical
or assay manufacturers were contacted to obtain relevant in-
formation in the public domain. Data on file, unpublished
observations, personal communications, and other forms of
data not previously published or presented in a scientific, public
forum were not considered for this report. Discussions of drugs
focused on those approved by the US Food and Drug Admin-
istration. Clinical recommendations were made by panel
consensus.
The quality and strength of the evidence were rated according
to a scale (table 1) that was modified in 2006 [9] and originally
adapted from published rating scales used by other organiza-
tions (e.g., the American Heart Association [10], American
Association for the Study of Liver Diseases [11], National In-
stitutes of Health [12], and Infectious Diseases Society of Amer-
ica [13]).
TRANSMISSION AND EPIDEMIOLOGY OF
DRUG-RESISTANT HIV-1
Transmission and prevalence of drug resistance in developed
countries. Transmission of drug-resistant HIV-1 has been ob-
served in most countries where antiretroviral treatment is avail-
able [14–22], and it jeopardizes the success of antiretroviral
therapy. Indeed, transmitted drug resistance generally leads to
a delay in virologic suppression [18, 23] and to an increased
risk of earlier virologic failure [24, 25]. Long-term persistence
of transmitted drug resistance in the absence of drug pressure
has been documented for many types of mutations [26–30],
as have specific revertant mutations for thymidine analogue
reverse-transcriptase inhibitor–associated resistance mutations
(TAMs) [29]. In contrast with patients with acquired drug-
resistant virus that emerged during therapy, patients with trans-
mitted drug-resistant virus do not have a reservoir of drug-
susceptible virus. Consequently, transmitted drug-resistant
virus can only change to drug-susceptible virus by back mu-
tation [30], and it will do so rapidly only if a substantial fitness
benefit occurs with reversion of the drug resistance mutation,
HIV/AIDS • CID 2008:47 (15 July) • 269
as in the case of the M184V mutation in reverse transcriptase.
This mutation can revert relatively early after transmission [26],
in contrast with the delayed reversion that occurs with most
other mutations [26, 30]. This delayed reversion is different
from the reversion associated with acquired drug resistance, in
which archived, drug-susceptible wild-type virus reemerges
within weeks of withdrawal of the selective pressure of drug
treatment [31–34].
The prevalence of newly transmitted drug-resistant HIV-1
strains (primary HIV-1 drug resistance) varies widely with lo-
cation, transmission risk group, and the sampling time after
infection [14, 15, 18, 20–23, 35–37]. Variations in prevalence
are multifactorial and reflect different treatment exposures at
the population level, potential selection bias caused by non-
representative sampling of certain transmission risk groups,
different definitions of resistance [38, 39], different sampling
times after infection, and different risk behavior and access to
therapy among transmission risk groups. A large increase in
overall primary resistance, from 13.2% for the period 1995–
1998 to 24.1% for the period 2003–2004, was reported in New
York, New York, and the rate of transmitted multidrug resis-
tance increased from 2.6% to 9.8% over the same period [36].
A British group also reported high rates of primary resistance
in 2003: 19.2% for any drug, 12.4% for nucleoside analogue
reverse-transcriptase inhibitors (NRTIs), 8.1% for nonnucleo-
side analogue reverse-transcriptase inhibitors (NNRTIs), and
6.6% for PIs. High-level resistance was found in 9.3%. In con-
trast, a representative 10-year transmission surveillance study
(1996–2005), conducted by the Swiss HIV Cohort Study,
showed considerably lower rates: 7.7% for any drug, 5.5% for
NRTIs, 1.9% for NNRTIs, and 2.7% for PIs. Dual– or triple–
drug class resistance was observed in only 2% of patients [21].
The rate of transmission, including the transmission of mul-
tidrug-resistant virus, was stable over a 10-year period, with
the exception of NNRTI-resistant virus transmission, which—
as has been reported by other groups—increased in 2005 [16,
18, 20, 36, 40]. These examples demonstrate that specific coun-
tries and regions require separate surveillance systems to mon-
itor transmitted HIV drug resistance, because extrapolation
from foreign data may be misleading.
The CASCADE study [41] has reported the longest follow-
up time for patients with transmitted drug resistance to date;
this study found higher initial CD4+ T cell counts in patients
infected with drug-resistant virus than in patients infected with
wild-type virus. This initial higher CD4+ T cell count was fol-
lowed by a faster decrease in CD4+ T cell count, such that initial
differences in CD4+ T cell counts were lost over the 5-year
observation period. Thus, the effects of transmitted drug-re-
sistant HIV on the infection’s natural history before treatment
are not great.
Drug resistance acquired during antiretroviral therapy is
much more common than transmitted drug resistance. Cross-
sectional studies involving patients who have been treated but
who are viremic yielded probabilities for the presence of at least
1 drug resistance mutation of 76%–90% [42–47]. However,
considerable methodologic challenges exist in evaluating such
prevalence data. Drug resistance testing can be reliably per-
formed only if plasma HIV-1 RNA levels are 1500 copies/mL.
This is particularly important if a patient’s plasma HIV-1 RNA
level was suppressed to below the level of detection before the
time that drug resistance testing became available, when pa-
tients initially received suboptimal treatment, such as single-
or double-NRTI–only regimens. Estimates of prevalence are
confounded, because the denominator of all treated patients is
often not known, the practice of obtaining drug resistance test
results has changed over time, and cross-sectional analyses may
underestimate the prevalence of drug resistance [48]. In a recent
10-year longitudinal study from the Swiss HIV Cohort Study,
which took into account shifts in population size and in which
the denominator of treated subjects was known, the prevalence
of drug-resistant virus among antiretroviral therapy–exposed
patients was estimated to be 50%–60% in 1999 and decreased
to 39%–53% in 2006 [49]. The prevalence of triple drug-re-
sistant virus remained stable at 5%. These lower numbers are
likely to be attributable to the improving efficacy of treatment.
Transmission and prevalence of drug resistance in devel-
oping countries. Access to antiretroviral drugs in the devel-
oping world is increasing rapidly, although only a fraction of
individuals who need therapy are currently receiving it. As in
the developed world, an increase in transmitted resistance will
lag behind an increase in acquired drug resistance. Nevertheless,
with (1) 13 million people receiving antiretroviral therapy; (2)
treatment failure defined by clinical end points [50]; and (3)
limited availability of assays for routine determination of
plasma HIV-1 RNA levels and for detecting drug resistance,
acquired and transmitted drug resistance in resource-limited
settings will present formidable challenges. Even more extensive
drug resistance may emerge in this setting than in the developed
world [50]. Some studies have already demonstrated the pres-
ence of drug-resistant virus in patients with recent infections
in developing countries [51]. The World Health Organization
is developing a surveillance program to provide early warning
of increasing rates of transmitted resistance and to facilitate
additional treatment options [52].
Single-dose nevirapine is widely used in the developing world
to prevent mother-to-child transmission of HIV-1, but it selects
for nevirapine-resistant HIV-1 in 40%–60% of mothers, as de-
tected by population sequencing within 6–8 weeks of admin-
istration [53], and this resistance may compromise subsequent
response to nevirapine-containing regimens [51, 52, 54, 55].
Children who are born with infection despite nevirapine pro-
phylaxis have a high risk of developing resistance to nevirapine,
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which limits their future treatment options [54]. Coadminis-
tration of other antiretroviral drugs with nevirapine may reduce
the risk of drug-resistant infection in adults and children [56].
A number of characteristics of antiretroviral use in resource-
poor settings will affect the level of acquired drug resistance
among treated patients. For example, in a Thai cohort receiving
a fixed-dose combination of stavudine-lamivudine-nevirapine
and infrequent monitoring, virologic failure was associated with
more resistance (190% of isolates had NNRTI- and lamivudine-
resistance–associated mutations, and 130% had TAMs) [57]
than would be expected in the developed world at the time of
first viral rebound [50], although less resistance was observed
in cohorts with more-intensive plasma HIV-1 RNA level mon-
itoring [58, 59]. In the absence of real-time viral load moni-
toring, 155% of patients in Uganda who received zidovudine-
lamivudine-abacavir within the Development of Antiretroviral
Therapy in Africa study and who had detectable viremia at
week 48 had 1–4 TAMs, as well as the M184V mutation [60].
Limited access to antiretroviral drug programs may encourage
some infected individuals to share their antiretroviral drugs
with others, which may lead to suboptimal dosing. Such un-
disclosed therapy is likely to be the cause of drug resistance in
certain populations entering antiretroviral therapy rollout pro-
grams. Pretreatment drug resistant infection was detected in
∼10% of a subset of the Development of Antiretroviral Therapy
in Africa study recipients in Uganda and Zimbabwe [61].
MECHANISMS OF ANTIRETROVIRAL DRUG
RESISTANCE
Since the previous guidelines were published [3], several new
drugs have been approved, and novel mechanisms of resistance
have been elucidated. This section will review some of these
advances.
Reverse-Transcriptase Inhibitors
Etravirine. Etravirine (TMC125) is a second-generation
NNRTI that exhibits activity against many viruses that are re-
sistant to first-line NNRTIs. Etravirine has favorable safety,
pharmacokinetic, and antiviral activity profiles in heavily treat-
ment-experienced HIV-1–infected patients [62–67]. The im-
pact of pretreatment phenotype and genotype on the virologic
response to etravirine at week 24 was examined in the DUET-
1 and DUET-2 clinical trials [68–71]. Thirteen baseline HIV-
1 reverse-transcriptase mutations were associated with resis-
tance to etravirine in the DUET analyses: V90I, A98G, L100I,
K101E/P, V106I, V179D/F, Y181C/I/V, and G190S/A [70, 71];
of note, V179T was also identified in a separate US Food and
Drug Administration analysis [72]. In the pooled DUET study
results, 70% of subjects had 0 or 1 baseline etravirine mutation,
whereas 15% had 3 baseline etravirine mutations. Notably,
the reverse-transcriptase K103N mutation, which is often seen
in virus obtained from patients who experience virologic failure
during efavirenz and nevirapine treatment and which confers
broad cross-resistance within the first-generation NNRTI class,
was not associated with etravirine resistance [72].
Virologic responses were seen in the DUET trials despite the
presence of single etravirine mutations [70, 71]. The impact of
most of these etravirine mutations depended on the simulta-
neous presence of Y181C; however, Y181C had an impact only
when present with1 additional mutation [70, 71, 73]. Having
a greater number of baseline etravirine-related mutations was
associated with a decreasing virologic response to etravirine,
particularly when 3 mutations were present [70, 74]. The
impact of specific etravirine mutational patterns on clinical
virologic responses has not been fully defined. No phenotypic
“cutoff” levels for clinical responses to etravirine are currently
available.
Antagonism among specific reverse-transcriptase mu-
tations. A potentially relevant and mechanistically interesting
antagonism among various thymidine analogue NRTIs, TAMs,
and the emergence of the tenofovir-associated K65R mutation
has been elucidated [75]. TAMs selected by zidovudine or sta-
vudine counteract the selection of the K65R mutation, although
TAMs and the K65R mutation do not appear on the same
genome because of competing mutational pathways. Thymidine
analogue NRTIs, such as zidovudine, may protect against the
emergence of the K65R mutation when combined with teno-
fovir, leading some clinicians to combine these agents. In con-
trast to HIV-1 drug resistance patterns described for tenofovir
and for the triple-NRTI regimen tenofovir-abacavir-lamivu-
dine, which selects for the K65R mutation more frequently, a
quadruple-drug regimen of tenofovir plus zidovudine-abacavir-
lamivudine in the COL40263 trial selected predominantly for
NRTI-associated TAMs in virus from patients in whom therapy
had failed [76].
Mutations in the connection and RNase H domains of re-
verse transcriptase. Mutations in the connection (E312Q,
G335C/D, N348I, A360I/V, V365I, T369I, A371V, A376S, and
E399D) and RNase H (Q509L) domains of reverse transcriptase
are selected by NRTI therapy (in addition to TAMs); these newly
recognized mutations, which are located outside of reverse tran-
scriptase regions covered by standard genotype assays, sub-
stantially increase resistance to zidovudine when TAMs are also
present [77–83]. They can increase cross-resistance to lami-
vudine, abacavir, and tenofovir (although to a much lesser ex-
tent) but do not increase resistance to stavudine or didanosine
[77–79]. NNRTIs (mainly nevirapine) are also affected [80, 82].
The Q509L and A371V/Q509L mutations with TAMs impair
the formation of RNase H cleavage products, which increases
zidovudine-monophosphate excision on RNA/DNA duplexes
by reducing template degradation. Q509L and A371V/Q509L
also increase the efficiency of excision of short RNA/DNA du-
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plexes [81]. The N348I mutation in the reverse-transcriptase
connection domain confers dual zidovudine-nevirapine resis-
tance via 2 interrelated mechanisms [82]. First, N348I decreases
the ability of nevirapine to inhibit HIV-1 reverse transcriptase;
second, N348I substantially decreases the rate of RNase H cleav-
age, which increases zidovudine-monophosphate excision by
reducing RNA/DNA template degradation. Furthermore, the
ability of nevirapine to stimulate RNase H is substantially re-
duced, compared with the wild-type enzyme. The N348I and
A360V mutations, in combination with TAMs, decrease the
efficiency of RNase H cleavage and increase the amount of
rescued reaction product after ATP-dependent excision. Mu-
tations N348I and A360V promote reverse-transcriptase dis-
sociation from an RNase H–competent complex, thereby re-
ducing RNA/DNA template degradation [83]. The N348I
mutation occurs relatively frequently and can emerge early dur-
ing therapy with regimens containing zidovudine and nevira-
pine [82]. The clinical impact of connection and RNase H
domain reverse-transcriptase mutations on virologic response
has not been determined.
PIs
Improved understanding of the importance of drug exposure
in PI activity and resistance has led to widespread use of low-
dose ritonavir boosting to increase drug levels, resulting in more
effective competition with viral substrates and reduced impact
of single mutations on drug activity. Large cohort data confirm
superior virologic suppression with ritonavir-boosted PI-con-
taining regimens, compared with unboosted PI-containing reg-
imens, in drug-naive patients [50]. The genetic barrier to re-
sistance (i.e., the number of mutations required for resistance
to develop combined with difficulty in their selection) is gen-
erally greater for ritonavir-boosted PI-containing regimens than
it is for unboosted PI-containing regimens. Resistance to ri-
tonavir-boosted PIs requires multiple mutations that vary
among PIs, and the degree of resistance depends on the number,
as well as the type, of mutations present [50, 73, 84, 85]. The
large number of mutations required for resistance makes the
selection of resistance to boosted PI regimens uncommon,
compared with the selection of resistance to NNRTI-containing
regimens, among drug-naive patients who are experiencing a
first regimen failure [50, 86]. Recently approved drugs, such
as darunavir and tipranavir, have improved virologic activity
in patients harboring PI-resistant HIV-1 [87–89].
Studies relating baseline (i.e., pretreatment) PI susceptibility
or mutations to virologic outcome have been performed for
boosted PI-containing regimens. Predictions of virologic suc-
cess can be made by measuring fold-change in susceptibility
(phenotype) or number and type of mutations (genotype). Ge-
notypic resistance scores and phenotypic clinical cutoff levels
derived from virologic outcome data are now available for dif-
ferent boosted PI-containing regimens [87–93]. Among these
regimens, the number and codon positions of PI mutations in
the resistance scores vary, with partial overlap among different
drugs. For example, the resistance scores of tipranavir-ritonavir
and darunavir-ritonavir both include mutations I84V and L33F
but differ with respect to many other mutations. Therefore,
virus harboring multiple PI mutations will show some degree
of reduced susceptibility to all boosted PI regimens, and the
clinical usefulness of each regimen may vary greatly. Phenotypic
resistance testing may be particularly beneficial in this setting.
The extent of both resistance and drug exposure affects PI
activity. Thus, considering both parameters might improve pre-
dictions of viral inhibition. The inhibitory quotient (i.e., the
ratio of the measured plasma minimum concentration value
divided by the IC50 value or IC90 value) characterizes this re-
lationship. Nevertheless, studies evaluating whether assays for
drug exposure add to the effectiveness of assays for resistance
have yielded conflicting results [94–99]. Inhibitory quotient
values better predict PI activity than do resistance or drug levels
alone in some, but not all, clinical studies. No randomized
studies have yet shown an overall benefit to using inhibitory
quotient calculations for PI dose adjustment in place of stan-
dard resistance testing.
In addition to mutations in the protease gene associated with
PI resistance, mutations in the gag cleavage site region, espe-
cially p7/p1 and p1/p6, can increase the viral fitness of viruses
resistant to PIs [100–103]. These mutations typically occur in
conjunction with drug resistance mutations in the protease gene
[104–106]. Specific patterns of cleavage-site mutations have
been described for certain PIs (e.g., A431V with L24I-M46I/L-
I54V-V82A, I437V with I54V-V82F/T/S, L449V with I54M/L/
S/T/A, and L449F/R452S/P453L with D30N-I84V). In contrast,
mutation P453L and the emergence of V82A were negatively
correlated [107]. Mutations in the C-terminal region of the
viral gag gene (K436E and/or I437T/V), located outside the
actual NC/p1 cleavage site, can be selected in vitro in the ab-
sence of conventional PI resistance mutations, and they can
confer resistance by merely changing the substrate of protease
and thereby increasing processivity of the enzyme [108]. These
mutations were also present in clinical isolates that had reduced
susceptibility to PIs but lacked major protease mutations.
Whether these cleavage-site mutations are of clinical relevance
and should be included in drug resistance assays remains to be
determined.
Entry Inhibitors
HIV-1 entry involves the interaction of gp120 with its primary
receptor, CD4, followed by binding to 1 of 2 chemokine re-
ceptors (chemokine receptor 5 [CCR5] or CXC chemokine
receptor 4 [CXCR4]) that serve as coreceptors [109]. Engage-
ment of the coreceptor triggers the assembly of the 2 heptad
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Figure 2. The left panel shows a typical inhibition curve of a suscep-
tible virus (solid line) with a typical competitive inhibitor (e.g., a protease
inhibitor). The IC50 value of the resistant virus (dotted line) is shifted to
the right (arrow). The right panel shows an example of a noncompetitive
inhibitor (e.g., a chemokine receptor 5 antagonist). The susceptible virus
(solid line) shows a typical inhibition curve, but in this case, the resistant
virus (dotted line) reaches a plateau. The maximum achievable percent
inhibition is shifted downward (arrow), but the curve does not shift to
the right; hence, the IC50 value remains unchanged.
repeats (HR-1 and HR-2) in the trimeric gp41 into a 6-helix
bundle that leads to the approximation and fusion of the cell
and virus membranes [110]. The third variable (V3) loop is
the major structural element of gp120 that determines core-
ceptor recognition and specificity, but regions outside of V3
contribute, as well [111–113].
Enfuvirtide. Enfuvirtide is a synthetic 36–amino acid oli-
gopeptide that inhibits HIV-1 entry by preventing the assembly
of HR-1 and HR-2 in the trimeric gp41 into a 6-helix bundle
[114]. The drug binds to the trimeric HR-1 complex, thereby
inhibiting fusion and blocking virus entry [115]. Resistance to
enfuvirtide is mediated by amino acid substitutions within HR-
1 at amino acid positions 36–45 of gp41 [116, 117]. The sub-
stitutions most frequently associated with resistance to enfu-
virtide include G36D/S/V/E, V38A/E/M, Q40H, N42T, and
N43D [118–120]. These mutations confer substantially reduced
binding of enfuvirtide to HR-1 and a substantial decrease in
antiviral activity in vitro [119]. In addition, the N126K and
S138A mutations in HR-2 may contribute to reduced suscep-
tibility to enfuvirtide [118]. Viruses carrying enfuvirtide resis-
tance mutations show reduced viral fitness in vitro in the ab-
sence of enfuvirtide [121]. Clonal analysis of plasma HIV-1
RNA obtained from patients receiving enfuvirtide in the ab-
sence of a fully suppressive antiretroviral regimen showed rapid
emergence of enfuvirtide resistance mutations [122]. The earlier
emergence of mutants with gp41 substitutions at amino acid
positions 36 and 38 suggests that these mutants may have an
initial fitness advantage over mutants with substitutions at co-
dons 40 and 43, which tended to emerge later.
Chemokine receptor antagonists. Small-molecule antago-
nists of the gp120-CCR5 interaction, such as maraviroc and
the investigational drug vicriviroc, are allosteric, noncompeti-
tive antagonists that bind to a similar site on CCR5 [123–125].
These drugs are potent inhibitors of HIV-1 [126, 127]. Mar-
aviroc is now approved in the United States for use in treat-
ment-experienced patients with exclusively R5 virus strains.
Phase III trials of vicriviroc are under way.
Resistance to CCR5 antagonists selected in vitro is mediated
by changes in HIV-1 gp120 that allow the envelope glycoprotein
to interact with the drug-bound form of CCR5. A variety of
amino acid substitutions associated with maraviroc and vicri-
viroc resistance have been described throughout the env gene;
most involve V3, but their effect on drug susceptibility depends
on the env backbone into which they are introduced [128, 129].
Phenotypically, resistance to the CCR5 antagonists manifests
not as a classic rightward shift of the IC50 curve but, rather, as
a plateau in the maximum achievable suppression of viral rep-
lication (figure 2). This plateau, referred to as the percent max-
imal inhibition, correlates with viral adaptation to use the in-
hibitor-bound form of CCR5 for entry [129, 130].
Few clinical isolates that are resistant to maraviroc or vicri-
viroc have been reported [131–133]. Overall, resistance of R5
virus appears to emerge slowly and is associated with mutations
in the V3 loop stem (and possibly elsewhere in the env gene),
similar to resistance that arises during in vitro passage exper-
iments. The particular mutations observed vary from isolate to
isolate. Thus, it is not yet possible to identify resistance to CCR5
antagonists on the basis of specific env mutations. Although
no signature mutations associated with maraviroc resistance
have yet been identified, changes at positions 13 and 26 in the
middle of the V3 loop appear to be important [130, 132, 134].
Likewise, data are insufficient to determine the extent of cross-
resistance within the class. In clinical trials, virologic failure of
CCR5 antagonists has been more frequently attributed to the
emergence and outgrowth of CXCR4-using viruses that pre-
existed as minority populations before the initiation of CCR5
antagonist therapy.
INSTIs
The INSTIs are a new class of antiretroviral drugs that selec-
tively target the HIV-1 integrase enzyme. Integrase catalyzes
numerous steps within the cytoplasm and nucleus of host cells
that allow proviral DNA to enter the nucleus and integrate into
host cellular DNA. This entire process is required for productive
HIV-1 replication. The approved drug raltegravir and other
candidate drugs that are in development inhibit the strand
transfer reaction.
Resistance to integrase inhibitors can emerge during treat-
ment failure. Phenotypic and genotypic assays have been de-
scribed that detect HIV-1 integrase resistance [135–137], but
plasma-based phenotypic and genotypic assays to detect HIV-
1 integrase inhibitor resistance are not yet clinically available.
As with PI resistance mutations, INSTI resistance mutations
are classified as either major or minor. Major mutations tend
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to be the primary contact residues for drug binding, based on
crystal structures, and have an effect on the drug susceptibility
phenotype. Major mutations are those selected first in the pres-
ence of the drug or those shown at the biochemical or virologic
level to lead to an alteration in drug binding or an inhibition
of viral activity or viral replication. Minor mutations generally
emerge later than major mutations and enhance the degree of
resistance or improve replicative fitness of the virus that con-
tains major mutations [73].
Raltegravir is a hydroxypyrimidinone carboxamide derivative
of the diketobutanoic acid family. It is approved in the United
States and in Europe for use in treatment-experienced HIV-1–
infected patients in combination antiretroviral regimens, based
on favorable safety, pharmacokinetic, and efficacy parameters
[138–143]. In phase II and III studies, virologic failure occurred
infrequently and was generally associated with the emergence
of resistance mutations [136]. In Merck protocol 005, a phase
II study of HIV-1–infected subjects with triple-class drug re-
sistance, genotyping by population sequencing was performed
at treatment failure. Phenotyping of patient-derived sequences
and site-directed mutants employed single-cycle infection as-
says on long-terminal repeat-responsive reporter cell lines.
Raltegravir failure was associated with integrase mutations
in 2 distinct genetic pathways, defined by 2 mutations, in-
cluding (1) a signature (major) mutation at either Q148H/K/
R or N155H and (2) 1 minor mutations unique to each
pathway. The major mutations all reduced susceptibility to ral-
tegravir and decreased viral replication capacity. Minor mu-
tations described in the Q148H/K/R pathway included L74M,
E138A, E138K, or G140S. These minor mutations consistently
enhanced the level of resistance to raltegravir and, when com-
bined with major mutations, improved viral replication capac-
ity in a subset of combinations. The most common mutational
pattern in this pathway is Q148H plus G140S. This Q148H-
plus-G140S pattern exhibited the greatest decrease of drug sus-
ceptibility ( 1100-fold phenotypic resistance) and was the fittest
variant seen (i.e., it had the highest replication capacity in both
infectivity and multiple-cycle replication assays).
Mutations described in the N155H pathway include this ma-
jor mutation plus 1 of either L74M, E92Q, T97A, E92Q plus
T97A, Y143H, G163K/R, V151I, or D232N [73, 136]. Mutations
observed in raltegravir protocols were similar to those selected
with different integrase inhibitors in cell culture [144, 145].
The impact of specific raltegravir mutational patterns on clin-
ical virologic responses has not been elucidated fully; thus, no
phenotypic cutoff levels for clinical response have been deter-
mined for raltegravir. The most important prognostic factor
that decreased the likelihood of virologic failure and drug re-
sistance was having a genotypic susceptibility score or phe-
notypic susceptibility score 10 for optimized background reg-
imen; thus, integrase inhibitors should always be paired with
other active agents in an HIV-1 treatment regimen [136].
HIV-1 DRUG RESISTANCE ASSAYS
There are 2 general types of resistance assays used in clinical
practice: genotypic assays (i.e., HIV-1 gene sequencing to detect
mutations that confer HIV-1 drug resistance) and phenotypic
assays (i.e., cell culture–based viral replication assays in the
absence or presence of drugs). Genotypic testing can be per-
formed with commercial assay kits or in-house protocols.
Blinded quality assurance programs indicate a very high con-
cordance between kits and in-house methods used [146–148].
The ability to detect drug-resistance mutations, however, can
vary substantially among laboratories [146, 149]. This wide
variation results from difficulties in recognizing viral mixtures,
particularly in heavily treatment-experienced patient popula-
tions [147, 150, 151], sequencing specimens with low viral
loads, and testing non–subtype B HIV [149]. Performance also
relates to the level of experience among laboratory personnel
[149], which suggests that appropriate operator training, cer-
tification, and periodic proficiency testing are important for
accurate genotyping. Resistance testing laboratories, therefore,
need to participate in quality assurance programs [146, 147,
149–152].
Despite numerous studies, appropriate interpretation of ge-
notypic and phenotypic drug resistance testing remains chal-
lenging. Results of genotypic tests use lists of predefined drug
resistance mutations [73] or classifications by computerized,
rules-based algorithms to characterize virus as “susceptible,”
“possibly resistant,” or “resistant” to each antiretroviral drug
[153–156]. The creation of rule-based algorithms is a difficult
and lengthy process, and the algorithms require frequent up-
dating. Algorithms vary considerably in the classification of
expected drug activity [150, 151, 156–159]. Differences appear
to be lowest for lamivudine and NNRTIs and highest for NRTIs
and PIs [150, 151]. The most stringent approach to building
algorithms is to evaluate the impact of mutational patterns at
the initiation of treatment with a specific drug with regard to
treatment response (e.g., decrease of plasma HIV-1 RNA levels
according to specific genotypic patterns). Considerable progress
has been made in identifying mutational baseline patterns that
predict clinical failure for specific drugs. These patterns are
currently available for the combinations lopinavir-ritonavir,
atazanavir-ritonavir, tipranavir-ritonavir, darunavir-ritonavir,
and amprenavir-ritonavir, as well as for zidovudine, stavudine,
didanosine, lamivudine, tenofovir, efavirenz, nevirapine, and
etravirine [70–72, 91–93, 157, 160–168]. The vast majority of
genotypic algorithms are based on data that were obtained using
subtype B viruses. Although no large differences exist with re-
gard to interpretation of drug resistance in non–subtype B HIV,
discrepancies between genotype and phenotype have been ob-
274 • CID 2008:47 (15 July) • HIV/AIDS
served for abacavir and subtype CRF02_AG, atazanavir and
subtype C, and NNRTIs and subtype CRF01_AE [169]. HIV-
1 proteases in drug-naive West African patients appear to be
generally less sensitive to PIs [170]. More in vivo and in vitro
resistance data are clearly needed for non–subtype B HIV.
An alternative approach for the interpretation of genotypic
drug resistance information is to correlate genotypic data re-
garding the plasma HIV-1 RNA of a candidate gene with a large
database of paired phenotypes and genotypes [171–174]. Such
linkage then permits generation of a “virtual phenotype” by
assigning calculated fold-changes in IC50. Although actual and
virtual phenotypes show excellent correlation for most drugs,
superiority of virtual phenotype over genotype alone could not
be demonstrated in predicting clinical response to salvage reg-
imens [173, 175, 176]. Virtual phenotype is an approach to
genotype interpretation, and its main limitation is that predic-
tive power depends on the number of matched datasets avail-
able. Thus, variation is frequently higher in smaller datasets;
consequently, variation is frequently higher for newer drugs.
Furthermore, matches are based on preselected codons, not on
the entire nucleotide sequence.
Standard phenotypic testing, using recombinant virus assays,
is performed by few commercial laboratories. Current assays
amplify HIV-1 protease, a part of the HIV-1 reverse transcrip-
tase, as well as the 3′-terminus of gag, as a unit from plasma
virus, and they generate a recombinant virus pseudovirus with
other HIV-1 genes derived from a laboratory construct [177–
181]. A comparison between 2 different assays showed an over-
all concordance of 86.9%, with the highest concordance for PIs
(93.4%) and the lowest concordance for NRTIs (79.8%) [150].
However, even within drug classes, concordance can vary widely
among specific drugs (e.g., lamivudine has a very high con-
cordance of 93%, but abacavir has a concordance of only 74%
[150]). This recombinant technology is being modified so that
it can also test for susceptibility to INSTIs, fusion inhibitors,
and chemokine receptor antagonists [136, 182].
The results of phenotypic testing are usually presented as the
fold-change in susceptibility of the test sample compared with
a laboratory control isolate. The initial “technical” cutoff values,
representing the interassay variation of cloned virus controls,
did not accurately reflect the inherent variation in susceptibility
encountered in circulating viruses from drug-naive patients.
The normal distribution of susceptibility to a given drug for
wild-type isolates from treatment-naive individuals (i.e., the
“biologic” cutoff) was then adopted. Although clinical cutoffs
have been defined for many drugs, the relationship between
viral susceptibility and drug response is a continuum in which
progressively reduced viral phenotypic susceptibility to a par-
ticular drug results in progressively blunted reductions in
plasma HIV-1 RNA levels. For practical application, 2 different
clinical phenotypic cutoff values should be defined: one above
which clinical responses perceptibly diminish, compared with
those of wild-type virus (“intermediate” resistance), and one
above which no clinical response can be expected (“full” re-
sistance). Even partial activity can be useful when treatment
options are limited [183]. In evaluation of phenotypic cutoffs,
drug-specific susceptibility needs to be compared at baseline,
before switching to a new drug regimen, and with the drug-
specific treatment response (e.g., decrease in plasma HIV-1
RNA levels) that occurs after initiation of new therapy. Since
2003, clinical trial and cohort data have led to a substantial
increase in available clinical cutoff values, and such values are
now available for most approved drugs.
In addition to standard genotypic and phenotypic testing
used in clinical practice, other resistance testing assays may
prove to be useful in the future. The allele-specific PCR assay
[184–189] and the single-genome [190] and ultra-deep se-
quencing [191] assays are currently used to investigate the role
of minority variants harboring drug resistance that are present
below the level of detection by bulk plasma viral population
sequencing approaches. Studies involving treatment-naive and
treatment-experienced patients have shown strong associations
between the detection of low-frequency drug-resistant variants,
particularly those encoding resistance to NNRTIs, and subse-
quent treatment failure [192–194]. Further studies are required
to define the clinically relevant frequency of variants in the
virus population. Improvements in assay throughput and re-
ductions in cost are necessary before such assays are available
for patient management.
Replication capacity assays, which are designed to measure
in vivo fitness of a virus, remain an interesting research tool,
but they have not found a role in patient management [195].
A relatively simple and inexpensive alternative for estimating
the reduction of in vivo fitness induced by a given nonsup-
pressive antiretroviral treatment regimen is to determine the
differences in plasma HIV-1 RNA levels between pretreatment
and on-treatment periods (e.g., for patients lacking fully sup-
pressive treatment options); such information may be useful
in optimizing a nonsuppressive treatment regimen [196]. Fi-
nally, the cost-effectiveness of using resistance testing assays for
treatment-naive patients and for patients for whom antiret-
roviral treatment has failed has been demonstrated in various
countries [197–202].
VIRAL CORECEPTOR USE TESTING
Phenotypic assays to determine coreceptor use (i.e., tropism
testing) require the amplification of env sequences from plasma
HIV-1 RNA and the construction of viral pseudotypes or in-
fectious recombinant viruses that express the patient-derived
env sequences along with a reporter gene [182]. These pseu-
dotyped viruses or viral recombinants are then inoculated onto
cells that express CD4 along with CCR5 or CXCR4. The pres-
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ence of infection is detected by assays that determine reporter-
gene activity. HIV-1 isolates that use CCR5 exclusively are
termed R5 viruses, those that use only CXCR4 are termed X4
viruses, and those that use both are termed R5/X4, or dual-
tropic viruses. Because these assays do not distinguish between
the presence of truly dual-tropic viruses and a mixture of R5
and X4 viruses, samples that can infect both CCR5- and
CXCR4-expressing cells are often termed dual-mixed viruses.
As with commercially available resistance tests, tropism testing
generally requires a plasma sample with an HIV-1 level of
1000 copies/mL. The assay used in most clinical trials of
CCR5 antagonists can detect the presence of CXCR4-using vi-
rus when they constitute at least 5%–10% of the virus popu-
lation as minor variants [182]. Assays with improved sensitivity
for detection of 0.3% CXCR4-using or dual-mixed virus are
now available [203].
Genotypic approaches to determining coreceptor use depend
on sequencing the V3 loop and applying one of a variety of
predictive algorithms. The 2 most commonly used measures
for predicting CXCR4 use include (1) the presence of positively
charged amino acids at positions 11 and 25, often referred to
as the “11/25 rule,” and (2) the total charge of V3 loop amino
acid residues of +5 or greater [204, 205]. Bioinformatic ap-
proaches include the use of position-specific scoring matrices
[206], neural networks [207], or machine-learning techniques
[208]. The heteroduplex tracking assay has also been used to
detect the presence of CXCR4-using virus [209]. In this assay,
the electrophoretic mobility of PCR-amplified env genes is as-
sayed after hybridization to V3-coding sequences from viruses
with phenotypically defined coreceptor use. When verified
against phenotypic assays, genotypic approaches showed ex-
cellent specificity but poor sensitivity for detecting the presence
of dual-mixed or CXCR4 viruses in clinical samples [210]. The
low sensitivity of these methods is explained, in part, by the
extensive heterogeneity of HIV-1 env genes in plasma virus
populations, which makes it difficult to obtain coherent se-
quence data with population-based sequencing approaches. An-
other contributing factor is that not all determinants of viral
tropism reside in the V3 loop. For these reasons, genotypic
approaches cannot be recommended at present for identifying
patients who may be suitable candidates for CCR5 antagonist
therapy. Other limitations of genotyping for coreceptor tropism
include the inability of population sequencing to detect variants
that comprise !25% of the virus population and the lack of
interpretation algorithms for sequences that are not from sub-
type B.
Drug Resistance in Non–Subtype B HIV
Antiretroviral drug design, resistance research, and interpre-
tation systems have been largely based on HIV-1 subtype B
viruses, which have historically been the most prevalent subtype
in North America, Western Europe, and Australia. However,
subtype B viruses account for only ∼12% of the worldwide
HIV-1 infections, with subtype C viruses being the most prev-
alent, accounting for ∼50% of cases [211]. An increasing num-
ber of individuals who are infected with many of the non–
subtype B virus strains now receive antiretroviral therapy
because of rollout programs in the resource-limited world and
because of increasing migration to the developed world, par-
ticularly to countries in Europe. It is essential to appreciate how
HIV-1 genetic variation alters the characteristics of drug sus-
ceptibility and drug resistance. The differences in the natural
polymorphisms between HIV-1 subtype B and non–subtype B
viruses have been well documented [212, 213]. The effects of
viral subtype on resistance are expressed in 2 broad cases: in
genetic routes to, and frequency of, specific mutations and in
the algorithms developed for interpreting drug resistance.
Genetic routes to and frequency of specific resistance
mutations. Viruses from patients infected with subtypes C,
G, or CRF_01 AE for whom a first-line nelfinavir-containing
regimen is failing preferentially select the L90M mutation,
rather than D30N, which more frequently occurs with subtype
B virus [214, 215]. This preferential selection of L90M in pro-
tease may stem from methionine polymorphism in these non–
subtype B viruses at position 89, rather than from lysine in
subtype B [216].
Synonymous differences are also responsible for different
resistance mutations. For example, valine at position 106 of
reverse transcriptase is coded by a GTG codon in subtype C,
in contrast with coding by a GTA codon in subtype B. Thus,
subtype C viruses more readily select methionine in the pres-
ence of efavirenz (a 1-nucleotide change), whereas subtype B
viruses change to an alanine (a 1-nucleotide change) [217]. The
V106M mutation is responsible for broad cross-resistance to
older NNRTIs [218]. A further example is at reverse transcrip-
tase position 210; subtype F viruses require 2 nucleotide sub-
stitutions for L210W to emerge, compared with the 1 mutation
required by other subtypes. This difference explains the lower
prevalence of L210W in cohorts of patients with subtype F
infection [219]. An even more intriguing finding is the in-
creased prevalence of K65R in reverse transcriptase from sub-
type C virus–infected patients receiving tenofovir or didano-
sine-containing regimens, compared with the prevalence in
reverse transcriptase from patients infected with other virus
subtypes. Although synonymous differences at reverse tran-
scriptase position 65 exist, these do not change the number of
substitutions required for the K65R mutation. One possible
explanation for this is that the longer string of adenines in the
reverse-transcriptase gene preceding the codon that codes for
K65 in subtype C viruses favors increased slippage of the re-
verse-transcriptase enzyme during transcription, thus encour-
aging mutations at position 65 [220, 221].
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Table 2. Summary of clinical situations in which resistance testing is recommended.
Clinical setting Comments
Before initiation of therapy
Primary (acute and early) infection Resistance testing is recommended. Initial therapy may be altered based on re-
sistance test results.
First evaluation of chronic HIV-1 infection Resistance testing is recommended, including for patients for whom therapy is
delayed, because plasma wild-type isolates may replace drug-resistant virus
with time in the absence of treatment.
Treatment initiation for chronic HIV-1 infection Resistance testing is recommended because of a rising prevalence of baseline
HIV-1 drug resistance in untreated patients with chronic infection [25], unless
preexisting data or stored samples for testing are available.
In antiretroviral-treated patients
Treatment failure Resistance testing is recommended. The decision to change therapy should in-
tegrate treatment history, new and prior resistance results (if available), and
evaluation of adherence and possible drug interactions.
In specific settings
Pregnancya Resistance testing is recommended before initiation of therapy to effectively
treat the mother and prevent mother-to-child transmission.
Other considerations and general recommendations Postexposure prophylaxis should consider treatment history and resistance data
from the source, when available;
A sudden increase in HIV-1 plasma RNA may reflect superinfection, possibly
with drug-resistant virus;
Plasma samples to be tested for drug resistance should contain at least 500
HIV-1 RNA copies/mL to ensure successful PCR amplification required for all
sequencing approaches;
It is preferable that the blood sample for resistance testing be obtained while
the patient is receiving the failing regimen, if possible;
Resistance testing should be performed by laboratories that have appropriate
operator training, certification, and periodic proficiency assurance;
Genotypic and phenotypic test results should be interpreted by individuals
knowledgeable in antiretroviral therapy and drug resistance patterns;
Inhibitory quotient testing is not recommended for clinical decision making.
a If resistance test results are available from before the pregnancy, clinical judgment should guide whether retesting for resistance is necessary.
Drug resistance algorithms for non–subtype B HIV.
The consensus sequence used for many algorithms, against
which changes are identified in sequences from tested patients,
is a subtype B sequence. This becomes problematic for subtypes
in which some “resistance” mutations actually reflect the wild-
type consensus for that subtype. This disparity is particularly
apparent for minor protease mutations. For instance, 6 subtype-
specific polymorphisms in protease (at positions 10, 20, 33, 36,
82, and 93) occur at sites known to be associated with drug
resistance in subtype B viruses. These amino acid substitutions
may represent the consensus sequence for more than 1 non–
subtype B virus, such as M36I in subtypes A, C, D, F, G, CRF01,
and CRF02. Most of the polymorphisms are located outside
the active site of the protease [222], such as M36I, which is
situated in the hinge region of the enzyme flap. Only in subtype
G is a polymorphism present in the active site of the enzyme
(V82I).
Several reports have suggested similar in vitro susceptibilities
to antiretroviral drugs among different group M subtypes [223,
224]. No differences in response to therapy among these sub-
types have been reported [195, 225]. The practical implication
of these polymorphisms is that resistance algorithms may over-
interpret resistance to specific drugs because of the inclusion
of these polymorphisms in the total number of identified re-
sistance mutations. This applies particularly to PIs, for which
the total number of mutations is often used to ascribe suscep-
tibility. Therefore, subtype determination should be included
in genotypic resistance testing. Because the selection of mu-
tations is incompletely characterized in non–subtype B viruses,
it would be beneficial to compare their sequences before treat-
ment and at treatment failure.
CLINICAL APPLICATIONS AND
RECOMMENDATIONS
Clinical applications and recommendations are shown in table
2. The essential strategy behind the use of resistance testing for
individual patient management is to provide information to
assist in the selection of antiretroviral regimens that achieve
and maintain virologic suppression—that is, plasma HIV-1
RNA levels below the lower limits of detection of the most
sensitive assays available for routine clinical use (50 copies/
mL).
HIV/AIDS • CID 2008:47 (15 July) • 277
Untreated, Established HIV-1 Infection
Because of the prevalence of primary HIV-1 resistance to an-
tiretroviral drugs in developed countries, resistance testing is
recommended for all patients at the time of diagnosis of HIV-
1 infection as part of the initial, comprehensive assessment
[AII]. This recommendation is not restricted to patients for
whom initiation of antiretroviral treatment is being considered
on the basis of clinical, immunologic, or virologic criteria. The
persistence of detectable mutations acquired at the time of HIV-
1 infection varies, with some (e.g., the reverse-transcriptase
K103N mutation) having the potential to persist for years and
others (e.g., the reverse-transcriptase M184V mutation) having
a greater potential for reversion [30]. Thus, establishing a drug-
susceptibility profile for a patient’s virus at the time of diagnosis
can be helpful in antiretroviral decision-making years later be-
cause of the ability of archived drug-resistant virus to reemerge
in cases of suboptimal therapy. Genotypic testing is recom-
mended [AIII] for the initial evaluation, because mutations that
may not yet have accumulated enough to affect phenotypic
susceptibility can be detected, HIV-1 subtype can be deter-
mined, and the cost of genotypic testing is lower than that for
phenotypic testing.
Treatment Failure
First or second treatment failure. Because of the high prev-
alence of infection due to drug-resistant virus among antiret-
roviral-treated patients with confirmed, detectable plasma virus,
drug resistance testing should be performed in all cases of treat-
ment failure [AI] (defined as an insufficient decrease or an
increase in plasma HIV-1 RNA level after 1–2 months of treat-
ment or a confirmed viral breakthrough in a patient with pre-
viously undetectable virus). However, genotypic and pheno-
typic resistance assays both have low amplification success rates
in specimens with plasma HIV-1 RNA levels !500 copies/mL.
Resistance to specific drugs may not always be detected if treat-
ment with the drug has been discontinued before the sample
is obtained, because resistant strains are often less fit than wild-
type virus and may persist only as undetectable minor sub-
species in the absence of drug pressure. Therefore, a specimen
for resistance testing should be obtained before treatment has
been discontinued or changed, and if treatment has been dis-
continued, the specimen should be obtained as quickly as pos-
sible thereafter. In addition, antiretroviral treatment history is
important, along with resistance data, in choosing the subse-
quent treatment regimen, especially if the treatment has been
discontinued for several weeks.
Resistance is not the only cause of treatment failure. Insuf-
ficient drug exposure, often resulting from incomplete adher-
ence to therapy, is the most common reason for failure of an
initial treatment regimen. However, continuing therapy in the
context of treatment failure will often lead to the emergence
and accumulation of additional resistance mutations. This ap-
plies particularly to drugs with low genetic barriers to resistance
(e.g., the NNRTIs, lamivudine, emtricitabine, enfuvirtide, and
raltegravir). Clinical resistance to ritonavir-boosted PIs often
emerges at a slower pace, requiring several mutations. There-
fore, rapid evaluation and prompt action should occur at the
time of treatment failure. For first and second treatment fail-
ures, genotypic resistance testing usually suffices, unless the
patient had initially acquired multidrug-resistant virus. Current
commercially available resistance assays report results for
NRTIs, NNRTIs, and PIs. Viral tropism assays that determine
whether a patient’s virus population is predominantly R5, X4,
or dual-mixed are used to indicate whether CCR5 antagonists
(e.g., maraviroc) may be an appropriate choice for patients with
treatment failure. Tropism determination may be useful in this
circumstance [BIII]. It is expected that susceptibility testing for
INSTIs (e.g., raltegravir) will be clinically available in the near
future.
Multiple treatment failures (advanced treatment failure).
In patients who experience multiple treatment failures, the virus
is often resistant to NRTIs, NNRTIs, and PIs. Until recently,
constructing potent alternative regimens that combined 2 or 3
fully active drugs was often impossible, despite the use of en-
fuvirtide, because of the high level of intraclass cross-resistance.
The increased availability of new drugs—including drugs from
existing classes but with low levels of intraclass cross-resistance,
such as darunavir and etravirine, and drugs from new classes,
such as maraviroc and raltegravir—have made the goal of at-
taining undetectable viral loads more realistic for patients with
numerous treatment failures [9]. In this situation, tropism de-
termination is recommended [AI], and phenotypic testing may
be a useful addition to genotypic testing, because the number
of mutations and the complexity of mutational interactions
may make genotypic interpretation challenging. However, phe-
notypic testing may not be available because of cost. Genotypic
testing is recommended for patients with multiple treatment
failures [AI], along with phenotypic testing, if available [AI].
The decision to change therapy and the selection of the new
regimen should be discussed with experts who are knowledge-
able in antiretroviral therapy, antiretroviral pharmacology, and
resistance patterns.
Special Circumstances
Acute and early phase HIV-1 infection. Genotypic resistance
testing is recommended for any patient who presents within
several months after HIV-1 infection because of the high re-
ported rates of transmitted drug resistance [AII]. If immediate
antiretroviral intervention is indicated, the initiation of treat-
ment should not be delayed until this result is available, because
the turnaround time may be2 weeks; rather, treatment should
be modified if the result demonstrates resistance to 1 com-
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ponent of the regimen. The initial choice of treatment should
also take into account the treatment history of the source pa-
tient and resistance data for that patient’s virus, if available. If
treatment is not initiated during the acute or early phases of
infection, the resistance test results will still be helpful in the
future, because early testing provides the best opportunity to
detect transmitted drug resistant virus that has been archived
and replaced by more-susceptible virus but which could emerge
later during treatment.
Pregnancy. Genotypic resistance testing is recommended
for all HIV-1–infected pregnant women with detectable plasma
virus, both for their own health and for the health of their
infants [AII]. This information will assist with treatment
choices for the mother, as well as with choices to prevent
mother-to-child HIV-1 transmission (including multidrug-re-
sistant HIV-1 transmission) by selecting a regimen that will be
effective and safe for the fetus.
Postexposure prophylaxis. The question of whether to ini-
tiate postexposure prophylaxis occurs primarily in 2 settings:
accidental exposure of a health care worker and high-risk sexual
exposure. In the former circumstance, drug resistance data from
the source may be useful in constructing a prophylactic regi-
men. In the case of high-risk sexual exposure, data on the source
are usually not available.
SUMMARY AND FUTURE DIRECTIONS
Antiretroviral drug resistance is present wherever antiretroviral
drugs are widely used, and as treatment rollout continues in
developing countries, the range of resistance will expand. The
incidence, prevalence, and transmission of drug-resistant vi-
ruses vary from country to country, and programs for world-
wide drug resistance surveillance should increase rapidly to
meet the emerging need. In developing countries, methods to
simplify specimen collection, storage, and testing should be
explored to facilitate better monitoring of individual patients
and community patterns.
The approval of several new antiretroviral drugs from dif-
ferent classes since our previous recommendations [3] has in-
creased the complexity of resistance testing and interpretation
in the developed world. Resistance testing for entry inhibitors
and INSTIs should be incorporated into routine management
when such testing becomes available and validated.
Techniques for resistance testing have become more stan-
dardized since our previous recommendations and have been
widely incorporated into routine management in the developed
world. Coreceptor tropism testing has also become available.
Future efforts should be made to increase the sensitivity of
these assays to better detect minor variants that may be of
clinical significance. Moreover, as resistance testing becomes
increasingly employed in developing countries, attention
should be given to detecting resistance patterns for non–sub-
type B strains of HIV and to establishing algorithms for eval-
uating their importance.
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